Core Viewpoint - Zhejiang Iwu Biological Technology Co., Ltd. has disclosed the progress of a lawsuit against Shanghai Lihui Equity Investment Partnership and others for violating stock reduction commitments, with a first-instance judgment ordering the defendants to pay 10.96 million yuan plus interest [1][3]. Group 1: Lawsuit Background and Progress - The lawsuit originated from Shanghai Lihui and others violating commitments related to stock reduction. The court accepted the case on September 6, 2024, with multiple defendants including Shanghai Lihui and Shanghai Yixu Medical Technology Co., Ltd. [2]. Group 2: First-instance Judgment Details - The Shanghai Pudong New Area People's Court ruled on October 31, 2025, that Shanghai Lihui must pay 10.96 million yuan within ten days of the judgment becoming effective, along with interest calculated based on specified rates from different dates [3]. - Shanghai Yixu is jointly liable for the payment, while claims against other defendants were dismissed. The case incurred a total of 114,900 yuan in court fees, to be shared by Shanghai Lihui and Shanghai Yixu [3]. Group 3: Other Litigation Matters - The company and its subsidiaries have two additional minor lawsuits not previously disclosed, with amounts of 833,100 yuan and 1,633,600 yuan, respectively. These minor lawsuits have not significantly impacted the company's operations [4].

关于公司涉及诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、案件所处的诉讼阶段：一审已判决 证券代码：300357 证券简称：我武生物 公告编号：2025-040 号 浙江我武生物科技股份有限公司 2、上市公司所处的当事人地位：原告 3、涉案的金额：10,961,305.35 元及利息 4、对上市公司损益产生的影响：截至本公告披露日，本案处于一审判决上 诉期内，一审判决尚未生效。目前无法预计对公司本期及期后损益或所有者权益 的影响。 一、本次诉讼的基本情况 浙江我武生物科技股份有限公司（以下简称"公司"或"原告"）就上海利 合股权投资合伙企业（有限合伙）违反承诺减持公司股票事项向上海市浦东新区 人民法院（以下简称"法院"）提起诉讼，并于 2024 年 7 月 5 日收到法院发出 的立诉前调解案号为（2024）沪 0115 民诉前调 66428 号的通知。详见公司在深 圳证券交易所网站和符合中国证监会规定条件的媒体上于 2024 年 7 月 8 日披露 的《关于公司涉及诉讼的公告》（公告编号：2024-017 号）。 20 ...

Core Viewpoint - Iwubio is a leading enterprise in the field of allergic disease diagnosis and treatment in China, holding over 80% market share in the desensitization treatment market, with strong technical barriers and brand advantages [1] Group 1: Business Performance - For Q3 2025, Iwubio reported revenue of 853 million yuan, ranking 16th among 34 companies in the industry, with the industry leader Changchun High-tech generating 9.807 billion yuan [2] - The main revenue source is dust mite drops, contributing 455 million yuan, accounting for 94.17% of total revenue [2] - The net profit for the same period was 335 million yuan, ranking 9th in the industry, with the top performer Tonghua Dongbao at 1.188 billion yuan [2][6] Group 2: Financial Ratios - As of Q3 2025, Iwubio's debt-to-asset ratio was 5.60%, down from 8.58% year-on-year, significantly lower than the industry average of 26.88% [3] - The gross profit margin stood at 95.37%, slightly up from 95.26% year-on-year, also higher than the industry average of 70.17% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.22% to 32,400, while the average number of shares held per shareholder increased by 6.63% to 14,900 [5] Group 4: Future Outlook - Iwubio's revenue for the first three quarters of 2025 increased by 16.86% year-on-year, with net profit rising by 26.67% [6][7] - The company expects steady growth in core product revenues, with projections for net profits of 390 million yuan, 470 million yuan, and 570 million yuan for 2025 to 2027, corresponding to dynamic P/E ratios of 45, 37, and 30 [6] - The company is expanding its pipeline, with promising results from clinical trials for its yellow flower sublingual drops [7]

Core Insights - The Social Security Fund has invested in 360 stocks by the end of Q3, with 32 stocks held for over 20 consecutive quarters, indicating a long-term investment strategy [1][2] Group 1: Investment Trends - The Social Security Fund has increased its holdings in 8 out of the 32 continuously held stocks, with significant increases in Hangyang Co., Yangnong Chemical, and Qixin Group, showing increases of 41.93%, 31.18%, and 18.76% respectively [2] - Conversely, 15 stocks saw a reduction in holdings, with notable decreases in Chengyi Pharmaceutical, Three Squirrels, and Chengde Lululemon, with reductions of 64.17%, 61.30%, and 56.24% respectively [2] Group 2: Industry Concentration - The 32 continuously held stocks are concentrated in the basic chemicals, pharmaceutical biology, and automotive sectors, with 6, 5, and 3 stocks respectively [2] - The basic chemicals sector includes stocks like Yangnong Chemical, Bluestar Technology, and Hangyang Co., while the pharmaceutical sector includes stocks like Wuwei Biological, Aide Biological, and Chengyi Pharmaceutical [2] Group 3: Performance Analysis - Among the 32 stocks, 20 reported a year-on-year increase in net profit, with Xiantan Co., China Jushi, and New Xing Casting showing significant growth rates of 72.48%, 67.51%, and 44.67% respectively [3] - Conversely, 11 stocks experienced a decline in net profit, with Zhongqi Co., Sanyou Chemical, and Three Squirrels showing declines of 622.16%, 69.18%, and 52.91% respectively [3]

Core Points - The Bioeconomy Index (970038) closed at 2277.51 points, down 0.16%, with a trading volume of 18.883 billion yuan and a turnover rate of 1.2% [1] - Among the index constituents, 23 stocks rose while 27 fell, with Iwubio leading the gainers at 6.71% and Meiya Optoelectronics leading the decliners at 3.02% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 225.09 yuan, and a market cap of 272.908 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 116.50 yuan, and a market cap of 47.525 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 31.97 yuan, and a market cap of 56.849 billion yuan [1] - Other notable constituents include Shishihistory (sz002252), Table Pharmaceutical (sz300347), and Muyuan Foods (sz002714) [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 871 million yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [3] - Key capital flows include: - Iwubio (300357) with a net inflow of 52.9277 million yuan from institutional investors [3] - Dabo Medical (002901) with a net inflow of 31.8434 million yuan from institutional investors [3] - Changchun High-tech (000661) with a net inflow of 27.6452 million yuan from institutional investors [3]

Group 1 - Iwubio's stock price increased by 5.17% on October 28, reaching 34.79 CNY per share, with a trading volume of 392 million CNY and a turnover rate of 2.37%, resulting in a total market capitalization of 18.215 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 4.58% during this period [1] - Iwubio, established on September 19, 2002, and listed on January 21, 2014, specializes in the research, production, and sales of products for the diagnosis and treatment of allergic diseases [1] Group 2 - The main revenue sources for Iwubio include dust mite drops (94.17%), Artemisia annua flowers (4.35%), skin prick solution (1.31%), research services (0.12%), and others (0.05%) [1] - Among the top ten circulating shareholders, a fund under Harvest Fund Management, Harvest Mutual Selected Stock A (006603), entered the list in the third quarter, holding 4.7118 million shares, which is 0.97% of the circulating shares [2] - The estimated floating profit for the fund today is approximately 8.0572 million CNY, with a floating profit of 6.8321 million CNY during the three-day increase [2] Group 3 - The fund manager of Harvest Mutual Selected Stock A is Hao Miao, who has been in the position for 6 years and 287 days, managing a total fund size of 5.342 billion CNY [3] - During his tenure, the best fund return was 183.83%, while the worst return was -30.55% [3]

Core Insights - The Social Security Fund has invested in 264 stocks by the end of Q3, with 91 stocks held for over 8 consecutive quarters, indicating a focus on long-term investments [1][2] Group 1: Investment Trends - The Social Security Fund has increased its holdings in 30 out of the 91 continuously held stocks, with significant increases in stocks like Dongfang Tantalum (167.89%), Weifu High Technology (102.60%), and Anhui Wuwei High-tech (86.33%) [2] - Conversely, 42 stocks saw a reduction in holdings, with notable decreases in Xinji Energy (88.17%), Mingtai Aluminum (77.19%), and Sophia (70.50%) [2] Group 2: Sector Analysis - The 91 stocks held by the Social Security Fund are concentrated in the pharmaceutical, basic chemicals, and power equipment sectors, with 15, 9, and 8 stocks respectively [2] - Key stocks in the pharmaceutical sector include Woofu Biology, Aide Biology, and Chengyi Pharmaceutical, while the basic chemicals sector features Yangnong Chemical, Blue Sky Technology, and Zhongqi Co., Ltd. [2] Group 3: Performance Metrics - Among the 91 stocks, 65 reported year-on-year profit growth, with significant increases from companies like Dajin Heavy Industry (214.63%), Shennong Development (202.82%), and Sanmei Co., Ltd. (183.66%) [3] - Conversely, 25 stocks experienced profit declines, with Zhongqi Co., Ltd. (-622.16%), Vanadium Titanium Co., Ltd. (-181.13%), and Three Squirrels (-52.91%) showing the largest decreases [3] Group 4: Long-term Holdings - The longest-held stocks by the Social Security Fund include Woofu Biology and Yangnong Chemical, held for 44 quarters since Q4 2014 [1] - Other notable long-term holdings include China Jushi (35 quarters), Sun Paper (31 quarters), and New Xing Foundry (30 quarters) [1]

Investment Rating - The report maintains an "Overweight" rating for several pharmaceutical companies including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Jiangsu Nhwa Pharmaceutical, with related targets such as CSPC Innovation Pharmaceutical [6][28]. Core Insights - The innovative drug sector is experiencing high prosperity, and the report continues to recommend innovative drugs and their industry chain. It highlights the recent global strategic collaboration between Innovent Biologics and Takeda, which is expected to catalyze the innovative drug market [6][29]. - The report notes that the A-Shares pharmaceutical sector underperformed the market in the fourth week of October 2025, with the SW Pharmaceutical and Biological index rising only 0.6% compared to a 2.9% increase in the SHCOMP [8][30]. - In the same period, the Hong Kong pharmaceutical sector also underperformed, while the U.S. pharmaceutical sector performed in line with the market [31][19]. Summary by Sections Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the ongoing recommendation of innovative drugs and the industry chain, maintaining "Overweight" ratings for various companies including Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, and Nhwa Pharmaceutical. It also recommends Biopharma/Biotech companies with innovative pipelines and increasing performance, maintaining "Overweight" ratings for Innovent Biologics, Xiamen Amoytop Biotech, and others [6][28]. Performance of A-Shares Pharmaceutical Sector - In the fourth week of October 2025, the A-Shares pharmaceutical sector's performance was weaker than the overall market, with a 0.6% increase compared to the SHCOMP's 2.9% rise. The medical service, pharmaceutical commerce, and medical equipment sub-sectors showed relatively better performance [8][30]. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector underperformed the market with a decline of 0.8%, while the U.S. pharmaceutical sector matched the market performance with a 1.9% increase. Notable stock movements included significant gains for companies like WuXi AppTec and declines for Alphamab Oncology in Hong Kong [31][19].

Core Insights - The Social Security Fund has invested in 157 stocks by the end of Q3, with 57 stocks held for over 8 consecutive quarters, indicating a preference for long-term investments [1][2] Group 1: Investment Trends - The Social Security Fund has increased its holdings in 23 of the 57 continuously held stocks, with significant increases in stocks like Dongfang Tantalum (167.89%), Wanwei High-tech (86.33%), and Sumida (70.56%) [2] - Conversely, 21 stocks saw a reduction in holdings, with notable decreases in Xinji Energy (88.17%), Mingtai Aluminum (77.19%), and Weifeng Electronics (64.38%) [2] Group 2: Sector Distribution - The 57 stocks held by the Social Security Fund are concentrated in the pharmaceutical, basic chemicals, and non-ferrous metals sectors, with 8, 6, and 6 stocks respectively [2] - The pharmaceutical sector includes stocks like Iwu Biological, Aide Biological, and Huate Dain [2] - The basic chemicals sector features stocks such as Lanxiao Technology, Zhongqi Co., and Wanwei High-tech [2] Group 3: Performance Metrics - Among the 57 stocks, 41 reported a year-on-year increase in net profit, with significant growth from companies like Shennong Development (202.82%), Wanwei High-tech (89.77%), and Chifeng Gold (86.21%) [3] - 15 stocks experienced a decline in net profit, with the largest decreases from Zhongqi Co. (622.16%), Vanadium Titanium Co. (181.13%), and Huawang Technology (49.46%) [3] - The sustainability of performance is observed in 23 stocks that have shown consistent year-on-year net profit growth over the past three years [3]

Summary of Iwu Biologics Conference Call Company Overview - **Company**: Iwu Biologics - **Industry**: Allergy Treatment and Biologics Key Financial Performance - **Revenue Growth**: - Q3 2025 revenue reached 369 million CNY, a year-on-year increase of 22.64% - Year-to-date revenue for the first three quarters was 853 million CNY, up 16.86% [2][3] - **Net Profit Growth**: - Q3 2025 net profit was 167.8 million CNY, a 36.44% increase year-on-year - Year-to-date net profit for the first three quarters was 345 million CNY, up 26.67% [2][3] Product Performance - **Dust Mite Drops**: - Revenue of 794.2 million CNY, a 13.38% increase year-on-year - New patient growth has not met expectations [2][3][5] - **Artemisia Annua**: - Revenue of 44.75 million CNY, a significant increase of 117.58%, with Q3 growth exceeding 180% [2][3] - **Skin Prick Products**: - Revenue of 11 million CNY from January to September, a 94.1% increase year-on-year [3] Sales and Marketing Strategies - **Sales Optimization**: - Increased resource allocation to sales and marketing, appointing capable personnel and enhancing regional analysis and supervision [4] - **Market Education**: - Focus on educating the market about desensitization therapy, particularly in southern China where dust mite allergies are prevalent [4][6] Clinical Pipeline Progress - **Clinical Trials**: - Dust Mite Ubenimex received clinical approval, with ongoing Phase I and II trials for other products [9] - **Stem Cell Projects**: - Rapid progress in stem cell projects, with a focus on developing proprietary serum and culture media [10][11] Competitive Landscape - **Market Dynamics**: - The desensitization market is large, with Iwu Biologics capturing only a small portion of the market [6] - **Impact of Competition**: - Increased competition is viewed positively as it aids in market education and expansion [6] Financial Outlook - **Expense Trends**: - Overall expense rates are expected to decline in 2025, although a rise is anticipated in Q4 due to seasonal factors [16] - **Future Projections**: - The company aims for sustainable growth through continued market focus and sales strategy optimization [22][24] Challenges and Opportunities - **New Patient Growth**: - New patient numbers for dust mite drops have not met expectations, while Artemisia Annua's growth aligns with seasonal demand [5][17] - **Market Penetration**: - The northern market for Artemisia Annua faces challenges due to seasonal symptoms and requires extensive academic promotion [19] Regulatory and Pricing Considerations - **Insurance Coverage**: - The entry of monoclonal antibody products into insurance may not negatively impact Iwu Biologics, as their treatment approach is complementary [21] - **Pricing Strategy**: - Pricing for new products is under consideration, with expectations for operational space if pricing exceeds certain thresholds [14] Conclusion - Iwu Biologics has demonstrated strong financial performance in 2025, driven by effective sales strategies and product development. The company is well-positioned to capitalize on market opportunities while navigating challenges in patient growth and competition. Future strategies will focus on sustainable growth and market education.